newsfilter
← Latest News
GlobeNewswire·

Shattuck Labs Announces Participation in Upcoming September Investor Conferences

  • Shattuck Labs, Inc. announced management participation in two upcoming investor conferences.
  • CEO Taylor Schreiber, M.D., Ph.D. & CFO Andrew Neill, M.B.A. will present at the Wells Fargo 21st Annual Healthcare Conference on September 8, 2026, at 11:00 AM ET.
  • The same executives will present at the Cantor Global Healthcare Conference on September 9, 2026, at 3:55 PM ET.
  • Both events will feature fireside chats & one-on-one meetings with webcasts available via the company website.
  • Shattuck Labs is a clinical-stage biotechnology firm developing first-in-class DR3 blocking antibodies for inflammatory & immune-mediated diseases.
  • The company's lead program is SL-325, a DR3 antagonist antibody designed to block the DR3/TL1A pathway.
  • The company maintains offices in Austin, Texas, & Durham, North Carolina.